Advice
in the absence of a submission from the holder of the marketing authorisation:
everolimus (Certican®) is not recommended for use within NHS Scotland.
Indication under review: Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
Medicine details
- Medicine name:
- everolimus (Certican)
- SMC ID:
- 1288/17
- Indication:
- Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 November 2017